Logo image of ART.MI

DEODATO GALLERY SPA (ART.MI) Stock Fundamental Analysis

Europe - BIT:ART - IT0005528937 - Common Stock

0.334 EUR
-0.01 (-1.76%)
Last: 10/14/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ART. ART was compared to 55 industry peers in the Hotels, Restaurants & Leisure industry. The financial health of ART is average, but there are quite some concerns on its profitability. ART has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ART had negative earnings in the past year.
ART had a positive operating cash flow in the past year.
ART.MI Yearly Net Income VS EBIT VS OCF VS FCFART.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 1M -1M -2M

1.2 Ratios

The Return On Assets of ART (1.05%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of 2.35%, ART is in line with its industry, outperforming 52.73% of the companies in the same industry.
ART has a Return On Invested Capital (3.16%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for ART is above the industry average of 11.28%.
The last Return On Invested Capital (3.16%) for ART is well below the 3 year average (13.79%), which needs to be investigated, but indicates that ART had better years and this may not be a problem.
Industry RankSector Rank
ROA 1.05%
ROE 2.35%
ROIC 3.16%
ROA(3y)6.18%
ROA(5y)N/A
ROE(3y)16.81%
ROE(5y)N/A
ROIC(3y)13.79%
ROIC(5y)N/A
ART.MI Yearly ROA, ROE, ROICART.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 20 40 60

1.3 Margins

With a Profit Margin value of 1.24%, ART perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
In the last couple of years the Profit Margin of ART has declined.
ART has a worse Operating Margin (2.74%) than 60.00% of its industry peers.
ART's Operating Margin has declined in the last couple of years.
ART has a Gross Margin of 25.49%. This is in the lower half of the industry: ART underperforms 67.27% of its industry peers.
In the last couple of years the Gross Margin of ART has declined.
Industry RankSector Rank
OM 2.74%
PM (TTM) 1.24%
GM 25.49%
OM growth 3Y-50.63%
OM growth 5YN/A
PM growth 3Y-57.05%
PM growth 5YN/A
GM growth 3Y-9.55%
GM growth 5YN/A
ART.MI Yearly Profit, Operating, Gross MarginsART.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ART is creating value.
The number of shares outstanding for ART remains at a similar level compared to 1 year ago.
ART has a worse debt/assets ratio than last year.
ART.MI Yearly Shares OutstandingART.MI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ART.MI Yearly Total Debt VS Total AssetsART.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ART has an Altman-Z score of 2.83. This is not the best score and indicates that ART is in the grey zone with still only limited risk for bankruptcy at the moment.
ART has a Altman-Z score of 2.83. This is in the better half of the industry: ART outperforms 74.55% of its industry peers.
ART has a debt to FCF ratio of 12.11. This is a negative value and a sign of low solvency as ART would need 12.11 years to pay back of all of its debts.
The Debt to FCF ratio of ART (12.11) is worse than 60.00% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that ART is not too dependend on debt financing.
ART's Debt to Equity ratio of 0.12 is amongst the best of the industry. ART outperforms 85.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 12.11
Altman-Z 2.83
ROIC/WACC0.42
WACC7.5%
ART.MI Yearly LT Debt VS Equity VS FCFART.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

ART has a Current Ratio of 1.96. This is a normal value and indicates that ART is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Current ratio value of 1.96, ART belongs to the best of the industry, outperforming 96.36% of the companies in the same industry.
ART has a Quick Ratio of 1.06. This is a normal value and indicates that ART is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ART (1.06) is better than 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.06
ART.MI Yearly Current Assets VS Current LiabilitesART.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

ART shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 400.00%, which is quite impressive.
Measured over the past years, ART shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -50.75% on average per year.
Looking at the last year, ART shows a very negative growth in Revenue. The Revenue has decreased by -14.67% in the last year.
ART shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.70% yearly.
EPS 1Y (TTM)400%
EPS 3Y-50.75%
EPS 5YN/A
EPS Q2Q%81.67%
Revenue 1Y (TTM)-14.67%
Revenue growth 3Y14.7%
Revenue growth 5YN/A
Sales Q2Q%-23.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ART.MI Yearly Revenue VS EstimatesART.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
ART.MI Price Earnings VS Forward Price EarningsART.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ART is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ART indicates a slightly more expensive valuation: ART is more expensive than 72.73% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 61.48
EV/EBITDA 17.67
ART.MI Per share dataART.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.05 0.1 0.15 0.2 0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ART does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DEODATO GALLERY SPA

BIT:ART (10/14/2025, 7:00:00 PM)

0.334

-0.01 (-1.76%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.11%
Inst Owner ChangeN/A
Ins Owners83.3%
Ins Owner ChangeN/A
Market Cap10.46M
Revenue(TTM)8.87M
Net Income(TTM)109.60K
Analysts80
Price Target0.87 (160.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.18
P/FCF 61.48
P/OCF 29.69
P/B 2.24
P/tB 2.82
EV/EBITDA 17.67
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY1.63%
OCF(TTM)0.01
OCFY3.37%
SpS0.28
BVpS0.15
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.05%
ROE 2.35%
ROCE 4.21%
ROIC 3.16%
ROICexc 4.55%
ROICexgc 5.99%
OM 2.74%
PM (TTM) 1.24%
GM 25.49%
FCFM 1.92%
ROA(3y)6.18%
ROA(5y)N/A
ROE(3y)16.81%
ROE(5y)N/A
ROIC(3y)13.79%
ROIC(5y)N/A
ROICexc(3y)18.08%
ROICexc(5y)N/A
ROICexgc(3y)22.97%
ROICexgc(5y)N/A
ROCE(3y)18.39%
ROCE(5y)N/A
ROICexgc growth 3Y-56.79%
ROICexgc growth 5YN/A
ROICexc growth 3Y-59.09%
ROICexc growth 5YN/A
OM growth 3Y-50.63%
OM growth 5YN/A
PM growth 3Y-57.05%
PM growth 5YN/A
GM growth 3Y-9.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 12.11
Debt/EBITDA 0.95
Cap/Depr 50.07%
Cap/Sales 2.05%
Interest Coverage 250
Cash Conversion 58.02%
Profit Quality 155.29%
Current Ratio 1.96
Quick Ratio 1.06
Altman-Z 2.83
F-Score7
WACC7.5%
ROIC/WACC0.42
Cap/Depr(3y)231.4%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)400%
EPS 3Y-50.75%
EPS 5YN/A
EPS Q2Q%81.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.67%
Revenue growth 3Y14.7%
Revenue growth 5YN/A
Sales Q2Q%-23.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y76.45%
EBIT growth 3Y-43.38%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y107.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.72%
OCF growth 3YN/A
OCF growth 5YN/A